Lexeo to Acquire Mantle Therapeutics in $21.3M Deal to Expand Friedreich's Ataxia Pipeline

Lexeo Therapeutics (NASDAQ:LXEO) has entered into a definitive agreement to acquire Mantle Therapeutics in a deal valued at up to $21.3 million, significantly expanding its pipeline for treating Friedreich's ataxia (FA). The announcement sent Lexeo shares up 5.4% in premarket trading on Tuesday.

Deal Structure and Terms

The acquisition agreement includes an upfront payment of $8.3 million in a combination of cash and equity to Mantle shareholders. The deal also includes up to $13.0 million in potential future payments contingent upon achieving specific clinical and regulatory milestones. The transaction is anticipated to close in the third quarter of 2026, according to the company's statement.

Strategic Rationale

This acquisition diversifies Lexeo's therapeutic approach to Friedreich's ataxia, a rare genetic neurodegenerative disorder, by adding programs that are not based on gene therapy. Lexeo gains four programs designed to increase or replace the frataxin protein, which is deficient in FA patients.

Ad

Key among the acquired assets is LX3010, a clinical-stage oral combination therapy. In a study involving 11 FA patients, LX3010 demonstrated a six-point improvement on the modified Friedreich's Ataxia Rating Scale (mFARS) at 16 weeks and a nine-fold increase in frataxin protein levels in muscle biopsies.

Pipeline and Outlook

Lexeo plans to advance one of the newly acquired programs into clinical development, with an Investigational New Drug (IND) application submission expected in 2027. The company also announced three new research collaborations with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy to explore cerebellar-targeted dosing of frataxin gene therapy.

Meanwhile, enrollment continues for the SUNRISE-FA 2 pivotal study of Lexeo's lead gene therapy candidate, LX2006, for FA-related cardiomyopathy, with topline data expected in the second half of 2027. Lexeo reiterated its financial guidance, stating its current cash runway extends into 2028. Following the news, Raymond James analyst Christopher Raymond reiterated a Strong Buy rating on the stock with a $24.00 price target, calling the acquisition a "cost-effective move" that provides "technological diversification."